



15 May, 2026

SYN-TECH CHEM.& PHARM.CO.,LTD

Industry Forum

Chen-Ming, Hsiao Chairman

 生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777



In these presentations and discussions, there are certain forward- looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.

We do not undertake any obligation to publicly revise or update any forward-looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.



CONTENTS

2026 INVESTOR CONFERENCE

This presentation will begin with a company brief introduction, review the operating results for year 2025 and the first quarter of 2026, and outline the company's future strategic plans and outlook.

01 Company Brief Introduction

Company profile

Main Products

DMF/MF Registration Status

Official and Customer Audit Records

P.04 — P.09

02 Performance for Operation

Business and Financial Statements

P.10 — P.20

03 Future Strategies and Forward - looking

Strategy in the Future Development & forward - looking

P.21 — P.23

01

Company Brief Introduction

-
- Company profile
 - Main products
 - DMF/MF registration status
 - Official and customer audit records



CORPORATE CORE VALUES

- Sincerity
- Honesty
- Development
- Innovation

FOUNDED

1982.11.09 established

CAPITAL

NT\$445,917 thousand

CHAIRMAN

Mr. Chen-Ming, Hsiao

EMPLOYEES

217 employees

BUSINESS DOMAINS

- APIs
- Animal Drugs
- Excipient

ALL-ROUND DEVELOPMENT

- Manpower cultivation
- Infrastructure
- Cooperate with academic units
- Develop new drugs with other enterprises

CERTIFICATIONS

- ISO 9001 Quality management systems
- ISO 14001 Environmental management systems
- ISO 45001 Occupational health and safety management systems
- PIC/S GMP Good Manufacturing Practice
- GDP Good Distribution Practice
- ISO 14064-1 Greenhouse Gas Protocol

AWARDS

National Award in Medicine Quality

National Award of Outstanding

Research and Development Award in Pharmaceutical Technology

National Innovation Award

Industrial Sustainable Excellence Award

Small and medium enterprise Innovation Award

National Innovation Award renewal

2024 Net-Zero Industry Competitiveness Superior Award

2025 Taipei Biotech Awards Go-Global Award - Special Mention Award

01 · PRODUCT PORTFOLIO

Main products



SYN-TECH CHEM. & PHARM.

Our ten major product lines cover key therapeutic areas including muscle relaxation, gastrointestinal, neurological, respiratory, and cardiovascular treatments, while also extending into veterinary pharmaceuticals and excipient businesses.

PRODUCT 01

Muscle Relaxants

PRODUCT 02

**Digestive System
Drugs**

PRODUCT 03

**Central Nervous
System Drugs**

PRODUCT 04

**Topical Anesthetic
Agents**

PRODUCT 05

**Excipient and
Animal Drugs**

PRODUCT 06

**Respiratory
System Drugs**

PRODUCT 07

**Chemotherapeutic
Drugs**

PRODUCT 08

**Cardiovascular
Agents**

PRODUCT 09

**Non-Steroidal Anti-
Inflammatory
Antipyretics &
Analgesics**

PRODUCT 10

Others

01 · DMF / MF REGISTRATION




COUNTRY	DMF/MF REGISTRATION
US U.S.A	20
JP JAPAN	21
CA CANADA	3
KR KOREA	6
EU EUROPEAN UNION	6
CN CHINA	4
+ OTHERS	9
TOTAL	69

GLOBAL DMF / MF FOOTPRINT

69

items global registrations, covering 7 major regional markets



01 · OFFICIAL AUDITS



SYN-TECH CHEM. & PHARM.

Successfully passed official inspections by eight major global regulatory authorities, with a cumulative total of **43** audit records, establishing a solid foundation for international regulatory compliance.

1995

U.S.A FDA

Number / Audit : **7**

2002

Taiwan FDA

Number / Audit : **22**

2007

Korea FDA

Number / Audit : **2**

2008

Hungary FDA

Number / Audit : **1**

2009

Australia TGA

Number / Audit : **4**

2014

Japan PMDA

Number / Audit : **5**

2015

Mexico FDA

Number / Audit : **1**

2016

E.U. EDQM

Number / Audit : **1**

01 · CUSTOMER AUDITS




CUSTOMER AUDITS

122

Cumulative Inspections Completed
(2020–2025)

Since 2023, the number of customer audits has increased significantly, reflecting international customers' strong confidence in Syn-Tech's product quality and supply reliability.



02

Performance for Operation


-
- Revenue of Recent 5 Years
 - Product / Regional Structure
 - Year-over-Year Operating Comparison
 - EPS and Dividend

02 · 5-YEAR REVENUE



SYN-TECH CHEM. & PHARM.

Unit : NT in million



2023 / 2022

+13.1%

2024 / 2023

+12.8%

2025 / 2024


+3.3%

02 · PRODUCT MIX 2025 vs 2024



SYN-TECH CHEM. & PHARM.

Unit : NT in ten thousand




02 · PRODUCT MIX 2026 Q1 vs 2025 Q1



SYN-TECH CHEM. & PHARM.

Unit : NT in ten thousand



02 · REGIONAL MIX · 2025

Data collected : Year 2025




■ Japan	40%
■ Asia (Except Taiwan and Japan)	20%
■ Europe	16%
■ Americas	13%
■ Taiwan	9%
■ Others	2%

02 · REGIONAL MIX · 2026 Q1



SYN-TECH CHEM. & PHARM.

Data collected : Jan.- Mar., 2026



■ Japan	43%
■ Asia (Except Taiwan and Japan)	19%
■ Europe	20%
■ Americas	8%
■ Taiwan	8%
■ Others	2%

Revenue Compared Between 2025 and 2024



Unit : NT in thousand

Operating revenue 1,300,241 ▲ + 3%	Operating profit 319,861 ▼ -9%	Profit after tax 261,609 ▼ -33%	EPS (in dollar) 5.87 ▼ -33%
---	---	--	--

ITEM	2025	2024	Differences (%)
Operating revenue	1,300,241	1,257,665	3
Gross profit	450,358	486,941	(8)
Gross profit ratio(%)	35	39	(10)
Operating profit	319,861	350,804	(9)
Non-operating income and expenses	14,059	137,434	(90)
Profit before tax	333,920	488,238	(32)
Profit after tax	261,609	393,284	(33)
EPS (in dollar)	5.87	8.82	(33)

The Differences Between 2025 and 2024



SALES GROWTH DRIVERS

The increase in revenue was mainly driven by **sales growth from exports to the Japanese market.**

OPERATING SUMMARY

This was mainly due to **price competition in export markets, exchange rate fluctuations, and adjustments in the product sales mix.**

NON-OPERATING INCOME

This was mainly attributable to reduced **claims revenue, lower currency exchange gains, and decreased interest income.**



Revenue Compared Between 2026 Q1 and 2025 Q1

Unit : NT in thousand

Operating revenue 275,573 ▼ -13%	Operating profit 77,735 ▼ -7%	Profit after tax 71,651 ▼ -5%	EPS (in dollar) 1.61 ▼ -5%
---	--	--	---

ITEM	Jan.- Mar., 2026	Jan.- Mar., 2025	Differences (%)
Operating revenue	275,573	315,750	(13)
Gross profit	111,194	116,398	(4)
Gross profit ratio(%)	40	37	8
Operating profit	77,735	83,274	(7)
Non- operating income and	11,829	11,448	3
Profit before tax	89,564	94,722	(5)
Profit after tax	71,651	75,751	(5)
EPS (in dollar)	1.61	1.70	(5)

The Differences Between 2026 Q1 and 2025 Q1



SALES GROWTH DRIVERS

- Due to climate changes, customers **adjusted their procurement schedules**, resulting in delayed **shipment timing**.
- **Price competition for certain products** affected market expansion.
- **Market strategies** were adjusted in response to changes in the market.


OPERATING SUMMARY

- Although revenue declined, **changes in the product sales mix led to an improvement in overall gross margin**.

EPS and Dividend in Recent 5 Years



Unit : NT in dollar



03

Future Strategies and Forward - looking

Strategy in the Future Development & forward - looking



Strategy in the Future Development & forward-looking I

PRODUCT MOMENTUM

Steady growth in product sales volume

Annual sales of AMH reached **3.8 metric tons**; DFP exceeded **1.9 metric tons** in sales; and NTP, actively expanding into the Japanese market, surpassed **2 metric tons**.

PROCESS OPTIMIZATION

Process optimization and automation of key manufacturing steps

Provide high-quality products at competitive prices.

01

Improve efficiency through process automation

CTT collaborated with the Development Center for Biotechnology (DCB) to promote process improvements and completed a preliminary automation plan for key production steps. This made the products more stable, with improved appearance and a milder odor during use, while reducing actual costs by **3%**.

02

Comprehensively upgrade factory facilities and equipment

The reconstruction of the factory and facilities has been completed. The three products, CMZ, OPS, and PEH, made significant contributions to revenue, generating **NT\$ 38 million**, and there are plans to continue introducing the production of EP, CZ, and other products.

03

Continuously contribute through the development of specialized products

Although sales of the TVP product were slightly below expectations, it still generated stable revenue **exceeding NT\$ 23 million**, demonstrating the contribution potential of specialized APIs.

Strategy in the Future Development & forward-looking II



Prudently evaluate future niche products

- 01** In alignment with national policy needs, strategically selected products with high strategic value are being developed. Among essential medicines, a new vasopressor agent, **EPR**, has been successfully developed.
- 02** Prioritize the development of essential medicines. For the **481** items on the list, the importance of demand is ranked according to urgency and criticality; currently, the **APB** product has been selected for initial development.
- 03** To prevent domestic drug shortages and ensure a stable supply for the healthcare system, the cardiovascular drug **MVC** has been selected to secure a stable supply in the future.
- 04** It is hoped that the government will implement incentive measures to alleviate financial pressure on the industry.
- 05** Promote the healthy and **sustainable development** of the industry.

Expand into new business areas

- 01** Evaluate key intermediates of APIs and strengthen R&D and process capabilities.
- 02** Expand into the **China market** and promote products such as CTT, AMH, and DFP. Among them, **CTT** has completed the application process and is currently in the sales phase.
- 03** Continue developing small-volume specialty APIs; **PRX** is a **cataract medication**, strengthening technological differentiation advantages.
- 04** Co-develop the new drug **GFH**, for which a license has already been obtained and development is ongoing. Provide APIs to STANDARD CHEM. & PHARM. CO., LTD., complete the export of the finished dosage form product to Japan, and continue the development of **SFM** for Parkinson's disease and **VIX** for antidepressant treatment.



SYN-TECH CHEM. & PHARM. CO., LTD

Thanks for your attention



生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777